Smallpox News and Research RSS Feed - Smallpox News and Research

Smallpox is a highly contagious disease caused by the variola virus, a member of the Orthopox virus family. It is one of the most devastating diseases known to humanity, with a mortality rate as high as 30%. In 1967, the World Health Organization embarked upon an intensified vaccination campaign to eliminate smallpox, which culminated in the successful eradication of the disease globally by 1980.

By the mid-1980s, there were only two known repositories of variola virus: the Institute of Virus Preparations in Russia, and the US CDC. The events in the US in September and October 2001 highlighted the risk that the variola virus might be used as an agent of bioterrorism. Governments around the world are taking precautionary measures to be ready to deal with a potential smallpox outbreak.
Region of the Americas becomes first in world to eradicate measles

Region of the Americas becomes first in world to eradicate measles

The Region of the Americas is the first in the world to have eliminated measles, a viral disease that can cause severe health problems, including pneumonia, blindness, brain swelling and even death. This achievement culminates a 22-year effort involving mass vaccination against measles, mumps and rubella throughout the Americas. [More]
Exposure to infections in early life not linked to higher mortality risk during adulthood

Exposure to infections in early life not linked to higher mortality risk during adulthood

A new biological study by the University of Stirling has found that exposure to infections in early life does not have long-lasting consequences for later-life survival and reproduction. [More]
SLU researchers study investigational vaccine for yellow fever

SLU researchers study investigational vaccine for yellow fever

Saint Louis University's Center for Vaccine Development is studying an investigational vaccine for yellow fever, a potentially deadly disease that is spread by the same mosquito that transmits Zika virus. [More]
First-ever vaccine to combat Leishmaniasis under development

First-ever vaccine to combat Leishmaniasis under development

As scientists scramble to get a Zika virus vaccine into human trials by the end of the summer, a team of researchers is working on the first-ever vaccine to prevent another insect-borne disease - Leishmaniasis - from gaining a similar foothold in the Americas. [More]
Scientists start clinical trial to test new prostate cancer vaccine

Scientists start clinical trial to test new prostate cancer vaccine

Oxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part. The first four participants have already received this experimental vaccine at the Churchill Hospital in Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield. [More]
Experimental vaccine shows effectiveness in Ebola vaccine trial

Experimental vaccine shows effectiveness in Ebola vaccine trial

An experimental vaccine combined with an innovative way of vaccinating people has resulted in an estimated 100 percent efficacy of the vaccine against the Ebola virus in West Africa -- and the approach could establish a new way of responding to outbreaks of emerging pathogens, including the Zika virus. [More]
PharmAthene to be compensated for loss of profits over SIGA's smallpox antiviral drug

PharmAthene to be compensated for loss of profits over SIGA's smallpox antiviral drug

PharmAthene, Inc. announced today that the Delaware Supreme Court affirmed the Delaware Court of Chancery's decision to award PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat. [More]
RBHS Chancellor leads study to eliminate chronic viral hepatitis

RBHS Chancellor leads study to eliminate chronic viral hepatitis

Chronic viral hepatitis has a reputation for being a silent killer. The infection often goes undetected until the symptoms of advanced liver cancer appear. By that point, a patient has a five-year survival rate, according to the American Cancer Society. [More]
Virologists demonstrate how poxviruses defeat the body's host immune defenses

Virologists demonstrate how poxviruses defeat the body's host immune defenses

Smallpox virus, which killed millions of humans through the ages, ranks among the world's most feared bioterrorism agents. Human monkeypox continues to occur sporadically in remote African villages. [More]
Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie

Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie

A phage is a virus that infects a bacterium. People often get very confused about what the difference is between a virus and a bacterium. A virus, like a bacterium, is also a microorganism, but unlike bacteria, it needs to have a host to be able to replicate and propagate. [More]
WHO officials hope to eradicate polio by 2024

WHO officials hope to eradicate polio by 2024

Shortly after the successful global Smallpox Eradication Programme (SEP) in the 80's, world leaders and public health officials announced a plan to eradicate poliomyelitis (polio) off the face of the Earth; the Pan American Health Organization and the World Health Organization (WHO) together championed the cause. [More]
Discovery could open up door for cancer research and treatment

Discovery could open up door for cancer research and treatment

Florida State University researchers have taken a big step forward in the fight against cancer with a discovery that could open up the door for new research and treatment options. [More]
GLOBVAC programme tests new vaccine that may provide complete protection against Ebola virus

GLOBVAC programme tests new vaccine that may provide complete protection against Ebola virus

The Research Council of Norway's Programme for Global Health and Vaccination Research (GLOBVAC) is co-funding testing of a new vaccine against Ebola that is drawing widespread international attention. The research programme has allocated NOK 20 million towards this work. [More]
First large field trial shows VSV-ZEBOV is effective against Ebola

First large field trial shows VSV-ZEBOV is effective against Ebola

A vaccine against the Ebola virus, tested in West Africa for the first time in a field trial, has proved to be effective. People who had come into close contact with someone recently infected, and who are therefore at particularly high risk, were vaccinated. [More]
Tests show VSV-ZEBOV vaccine safe and effective against Ebola

Tests show VSV-ZEBOV vaccine safe and effective against Ebola

Tests of the experimental Ebola vaccine VSV-ZEBOV in over 7500 participants in Guinea suggest that the vaccine provides high protection against the disease as early as ten days after vaccination, in adults who have potentially been exposed to the virus by coming in close contact with a recently infected person. [More]
Guinea Phase III trial shows VSV-EBOV vaccine highly effective against Ebola

Guinea Phase III trial shows VSV-EBOV vaccine highly effective against Ebola

Results from an interim analysis of the Guinea Phase III efficacy vaccine trial show that VSV-EBOV (Merck, Sharp & Dohme) is highly effective against Ebola. [More]
Ebola vaccine study begins in Dakar, Senegal

Ebola vaccine study begins in Dakar, Senegal

A trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial immunisations started at the Jenner Institute, Oxford University. The announcement comes as a conference in Oxford discusses the global response to Ebola and the implications for future drug and vaccine development. [More]
Vaccines - a needle-free future? An interview with Thomas Johnston and Dr. Kees Leenhouts, Mucosis

Vaccines - a needle-free future? An interview with Thomas Johnston and Dr. Kees Leenhouts, Mucosis

Scientists recognize that 90% of pathogens actually enter the body through the mucosa and secondly, we have evolved a mucosal defense system that can be used to defend against disease... [More]
Sheffield scientists to showcase novel medical discoveries during International Clinical Trials Day

Sheffield scientists to showcase novel medical discoveries during International Clinical Trials Day

WORLD-leading researchers and scientists from Sheffield Teaching Hospitals Foundation Trust and the University of Sheffield will be giving people in Sheffield and beyond a unique insight into how they can contribute to groundbreaking medical discoveries during International Clinical Trials Day (Wednesday 20 May 2015). [More]
European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

The European Investment Bank (EIB), the world’s largest multilateral bank, today reaffirmed its firm commitment to respond to the Ebola pandemic. The Bank has provided a EUR 50 million loan to Bavarian Nordic, an international biopharmaceutical company, for accelerated development of an Ebola vaccine with long-term efficacy. The financing is also backing research into vaccines for treating other infectious diseases and multiple cancer indications. [More]
Advertisement
Advertisement